Cubist Systematic Strategies’s Juno Therapeutics, Inc. JUNO Stock Holding History

Cubist Systematic Strategies’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-108	Closed	-$2K	–	2010
2017 Q1	$2K	Buy	+108	New	+$2.32K	﹤0.01%	1596
2016 Q4	–	Sell	-36,007	Closed	-$1.08M	–	2007
2016 Q3	$1.08M	Buy	36,007 +23,069	+178%	+$718K	0.07%	388
2016 Q2	$497K	Buy	+12,938	New	+$537K	0.03%	772
2015 Q3	–	Sell	-7,107	Closed	-$379K	–	2137
2015 Q2	$379K	Buy	+7,107	New	+$377K	0.02%	1090

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cubist Systematic Strategies's JUNO Position: Q2 2017 in Review

Cubist Systematic Strategies sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 108 shares — an estimated $2K sold.

Cubist Systematic Strategies first reported a position in JUNO in Q2 2015 and held it in 4 quarters. The position peaked at $1.08M in Q3 2016. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

Cubist Systematic Strategies reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Cubist Systematic Strategies sold 108 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $2K.
Cubist Systematic Strategies first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 4 quarters.
Cubist Systematic Strategies's Juno Therapeutics, Inc. position peaked at $1.08M in Q3 2016.
173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on Cubist Systematic Strategies's 13F filing for Q2 2017, filed 14 Aug 2017.